EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 181 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.720) is normal, around the industry mean (2.904). P/E Ratio (-3.864) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GMAB declined for three days, in 208 of 293 cases, the price declined further within the following month. The odds of a continued downward trend are 71%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 147 of 213 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.444) is normal, around the industry mean (2.904). P/E Ratio (41.171) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (440.869).
EDIT | GMAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 99 | 59 | |
PRICE GROWTH RATING 1..100 | 69 | 34 | |
P/E GROWTH RATING 1..100 | 41 | 3 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EDIT's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for GMAB (93) in the null industry. This means that EDIT’s stock grew somewhat faster than GMAB’s over the last 12 months.
GMAB's Profit vs Risk Rating (72) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to EDIT’s over the last 12 months.
GMAB's SMR Rating (59) in the null industry is somewhat better than the same rating for EDIT (99) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than EDIT’s over the last 12 months.
GMAB's Price Growth Rating (34) in the null industry is somewhat better than the same rating for EDIT (69) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than EDIT’s over the last 12 months.
GMAB's P/E Growth Rating (3) in the null industry is somewhat better than the same rating for EDIT (41) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than EDIT’s over the last 12 months.
| EDIT | GMAB | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 51% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 81% | N/A |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 65% |
| Advances ODDS (%) | 2 days ago 80% | 11 days ago 64% |
| Declines ODDS (%) | 4 days ago 90% | 29 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 69% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 0 FA rating(s) are green while GMAB’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).
EDIT (@Biotechnology) experienced а -7.80% price change this week, while GMAB (@Biotechnology) price change was -3.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.
EDIT is expected to report earnings on Nov 09, 2026.
GMAB is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | -0.72% | ||
| AXON - GMAB | 47% Loosely correlated | +1.83% | ||
| PRME - GMAB | 42% Loosely correlated | +9.23% | ||
| VIR - GMAB | 41% Loosely correlated | +4.90% | ||
| PCVX - GMAB | 40% Loosely correlated | +8.01% | ||
| EDIT - GMAB | 39% Loosely correlated | +4.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| WBETH.X | 2687.017800 | 166.974610 | +6.63% |
| Wrapped Beacon ETH cryptocurrency | |||
| BNT.X | 0.295636 | 0.011131 | +3.91% |
| Bancor cryptocurrency | |||
| HIFI.X | 0.001737 | -0.000005 | -0.28% |
| Hifi Finance cryptocurrency | |||
| SAND.X | 0.045329 | -0.000442 | -0.97% |
| The Sandbox cryptocurrency | |||
| GLMR.X | 0.007810 | -0.000147 | -1.84% |
| Moonbeam cryptocurrency | |||